Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 118

Similar articles for PubMed (Select 24090633)

1.

Erythropoiesis-stimulating agents in chronic kidney disease: what have we learned in 25 years?

Hung SC, Lin YP, Tarng DC.

J Formos Med Assoc. 2014 Jan;113(1):3-10. doi: 10.1016/j.jfma.2013.09.004. Epub 2013 Oct 3. Review.

PMID:
24090633
2.

Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.

Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, Wiebe N, Strippoli GF.

Cochrane Database Syst Rev. 2014 Dec 8;12:CD010590. doi: 10.1002/14651858.CD010590.pub2. Review.

PMID:
25486075
3.

2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.

Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, Kuriyama S, Komatsu Y, Suzuki M, Nakai S, Hattori M, Babazono T, Hiramatsu M, Yamamoto H, Bessho M, Akizawa T.

Ther Apher Dial. 2010 Jun;14(3):240-75. doi: 10.1111/j.1744-9987.2010.00836.x.

PMID:
20609178
4.

The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?

Singh AK.

Am J Kidney Dis. 2008 Dec;52(6 Suppl):S5-13. doi: 10.1053/j.ajkd.2008.09.010.

PMID:
19010260
5.

Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis.

Koulouridis I, Alfayez M, Trikalinos TA, Balk EM, Jaber BL.

Am J Kidney Dis. 2013 Jan;61(1):44-56. doi: 10.1053/j.ajkd.2012.07.014. Epub 2012 Aug 22.

6.

Anemia trials in CKD and clinical practice: refining the approach to erythropoiesis-stimulating agents.

de Francisco AL, PiƱera C.

Contrib Nephrol. 2011;171:248-54. doi: 10.1159/000327173. Epub 2011 May 23. Review.

PMID:
21625120
7.

Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.

Maddux FW, Shetty S, del Aguila MA, Nelson MA, Murray BM.

Ann Pharmacother. 2007 Nov;41(11):1761-9. Epub 2007 Sep 25.

PMID:
17895328
8.

Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease.

Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, Pellegrini F, Ravani P, Jardine M, Perkovic V, Graziano G, McGee R, Nicolucci A, Tognoni G, Strippoli GF.

Ann Intern Med. 2010 Jul 6;153(1):23-33. doi: 10.7326/0003-4819-153-1-201007060-00252. Epub 2010 Jun 24. Review.

PMID:
20439566
9.

Are there implications from the Trial to Reduce Cardiovascular Events with Aranesp Therapy study for anemia management in dialysis patients?

Berns JS.

Curr Opin Nephrol Hypertens. 2010 Nov;19(6):567-72. doi: 10.1097/MNH.0b013e32833c3cc7. Review.

PMID:
20601876
11.

Erythropoiesis-stimulating agents, hypertension and left ventricular hypertrophy in the chronic kidney disease patient.

Schmid H, Schiffl H, Lederer SR.

Curr Opin Nephrol Hypertens. 2011 Sep;20(5):465-70. doi: 10.1097/MNH.0b013e3283497057. Review.

PMID:
21738032
12.
13.

Individualizing decision-making--resurrecting the doctor-patient relationship in the anemia debate.

Agarwal R.

Clin J Am Soc Nephrol. 2010 Jul;5(7):1340-6. doi: 10.2215/CJN.02830310. Epub 2010 May 6.

14.

What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level?

Singh AK.

Curr Opin Nephrol Hypertens. 2010 Sep;19(5):420-4. doi: 10.1097/MNH.0b013e32833cf1d6. Review.

PMID:
20689425
15.
16.

Optimizing anemia management in hospitalized patients with end-stage renal disease.

Heung M, Mueller BA, Segal JH.

Ann Pharmacother. 2009 Feb;43(2):276-82. doi: 10.1345/aph.1L195. Epub 2009 Jan 13. Review.

PMID:
19141655
17.

An economic evaluation of erythropoiesis-stimulating agents in CKD.

Clement FM, Klarenbach S, Tonelli M, Wiebe N, Hemmelgarn B, Manns BJ.

Am J Kidney Dis. 2010 Dec;56(6):1050-61. doi: 10.1053/j.ajkd.2010.07.015. Epub 2010 Oct 8.

PMID:
20932621
18.

Erythropoiesis stimulating agents and anaemia of end-stage renal disease.

Schmid H, Schiffl H.

Cardiovasc Hematol Agents Med Chem. 2010 Jul;8(3):164-72. Review.

PMID:
20443766
19.

Safety issues related to erythropoiesis-stimulating agents used to treat anemia in patients with chronic kidney disease.

Del Vecchio L, Locatelli F.

Expert Opin Drug Saf. 2012 Nov;11(6):923-31. doi: 10.1517/14740338.2012.712680. Epub 2012 Aug 23. Review.

PMID:
22916722
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk